Literature DB >> 8523073

Genetic alterations in gliomas.

V P Collins1.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 8523073     DOI： 10.1007/bf01052656

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  9 in total

1.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

Authors:  N Sugawa; A J Ekstrand; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification.

Authors:  A J Ekstrand; N Longo; M L Hamid; J J Olson; L Liu; V P Collins; C D James
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

3.  A common region of homozygous deletion in malignant human gliomas lies between the IFN alpha/omega gene cluster and the D9S171 locus.

Authors:  K Ichimura; E E Schmidt; N Yamaguchi; C D James; V P Collins
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

4.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

5.  Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2.

Authors:  G Reifenberger; J Reifenberger; K Ichimura; P S Meltzer; V P Collins
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

Review 6.  Gene and chromosomal alterations associated with the development of human gliomas.

Authors:  V P Collins; C D James
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

7.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

8.  CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.

Authors:  J He; J R Allen; V P Collins; M J Allalunis-Turner; R Godbout; R S Day; C D James
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

9.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

Authors:  G Reifenberger; L Liu; K Ichimura; E E Schmidt; V P Collins
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701
  9 in total
  2 in total

1.  Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

Authors:  B Neyns; J Sadones; C Chaskis; M Dujardin; H Everaert; S Lv; J Duerinck; O Tynninen; N Nupponen; A Michotte; J De Greve
Journal:  J Neurooncol       Date:  2010-09-25       Impact factor: 4.130

2.  Reduced beta-catenin expression is associated with good prognosis in Astrocytoma.

Authors:  Li-Ying Zhang; Li-Na Jiang; Fan-Fan Li; Hang Li; Fang Liu; Yu Gu; Yue Song; Feng Zhang; Jing Ye; Qing Li
Journal:  Pathol Oncol Res       Date:  2009-12-11       Impact factor: 3.201
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.